
BFAGY
Healthcare · Drug Manufacturers - Specialty & Generic · $78.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2021
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 30, 2022 | After the close | — | 2.15 | — |
| Nov 25, 2021 | After the close | -0.22 | -0.24 | -9.1% |
| Jul 6, 2021 | Before the open | -0.21 | -0.17 | +19.0% |
| Apr 12, 2021 | After the close | -0.13 | -0.22 | -69.2% |
| Nov 11, 2020 | After the close | -0.34 | -0.28 | +17.6% |
| Aug 26, 2020 | After the close | -0.16 | 0.00 | +100.0% |
| Apr 20, 2020 | After the close | -0.11 | -0.22 | -100.0% |
| Nov 19, 2019 | Before the open | -0.33 | -0.56 | -69.7% |
| Aug 27, 2019 | Before the open | -0.24 | 0.58 | +341.7% |
| May 29, 2019 | Before the open | -0.23 | -0.14 | +39.1% |
| Jan 22, 2019 | Before the open | -0.13 | 0.18 | +238.5% |
| Nov 16, 2018 | Before the open | -0.17 | -0.23 | -35.3% |
| Aug 31, 2018 | Before the open | -0.19 | -0.24 |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern…
| -26.3% |
| Apr 30, 2018 | Before the open | -0.17 | -0.20 | -17.6% |